Literature DB >> 7917699

Thrombolysis of a modified Blalock-Taussig shunt with recombinant tissue plasminogen activator in a newborn infant with pulmonary atresia and ventricular septal defect.

M Ries1, H Singer, M Hofbeck.   

Abstract

A 10 day old infant with pulmonary atresia, ventricular septal defect, and collateral pulmonary blood supply through a left sided ductus arteriosus developed complete shunt thrombosis four days after the creation of a modified Blalock-Taussig shunt. Recombinant tissue plasminogen activator was given locally into the proximal end of the shunt as two bolus injections of 0.1 mg/kg and two bolus injections of 0.2 mg/kg over 10 minutes, followed by a continuous infusion of 1.4 mg/kg/day for 16 hours and 0.7 mg/kg/day for 18 hours with systemic low dose heparin 5 IU/kg/h. This resulted in complete clot dissolution and reperfusion without haemorrhagic complications and without laboratory signs of systemic fibrinolytic activation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7917699      PMCID: PMC1025490          DOI: 10.1136/hrt.72.2.201

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  10 in total

1.  Thrombolysis with recombinant tissue-type plasminogen activator in renal venous thrombosis in infancy.

Authors:  U Nowak-Göttl; D Schwabe; W Schneider; R Schlösser; W Kreuz
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321

Review 2.  Plasminogen activators. The old and the new.

Authors:  M S Runge; T Quertermous; E Haber
Journal:  Circulation       Date:  1989-02       Impact factor: 29.690

3.  Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator.

Authors:  H S Mueller; A K Rao; S A Forman
Journal:  J Am Coll Cardiol       Date:  1987-09       Impact factor: 24.094

4.  Differences in the binding to fibrin of urokinase and tissue plasminogen activator.

Authors:  S Thorsen; P Glas-Greenwalt; T Astrup
Journal:  Thromb Diath Haemorrh       Date:  1972-08-31

Review 5.  Thrombolytic therapy: current status (1).

Authors:  V J Marder; S Sherry
Journal:  N Engl J Med       Date:  1988-06-09       Impact factor: 91.245

6.  Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.

Authors:  M Hoylaerts; D C Rijken; H R Lijnen; D Collen
Journal:  J Biol Chem       Date:  1982-03-25       Impact factor: 5.157

Review 7.  Tissue plasminogen activator: a new thrombolytic agent.

Authors:  S J Crabbe; C C Cloninger
Journal:  Clin Pharm       Date:  1987-05

8.  Thrombolysis with tissue-type plasminogen activator following cardiac surgery in children.

Authors:  A Asante-Korang; N Sreeram; R McKay; R Arnold
Journal:  Int J Cardiol       Date:  1992-06       Impact factor: 4.164

9.  Tissue plasminogen activator for the treatment of thromboembolism in infants and children.

Authors:  M Levy; L N Benson; P E Burrows; Y Bentur; D K Strong; J Smith; D Johnson; S Jacobson; G Koren
Journal:  J Pediatr       Date:  1991-03       Impact factor: 4.406

10.  Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy.

Authors:  C D Naylor; P W Armstrong
Journal:  CMAJ       Date:  1989-06-01       Impact factor: 8.262

  10 in total
  5 in total

1.  Catheter-based interventions for modified Blalock-Taussig shunt obstruction: a 20-year experience.

Authors:  Mathilde Bonnet; Jérôme Petit; Virginie Lambert; Philippe Brenot; Jean-Yves Riou; Claude-Yves Angel; Emre Belli; Alban-Elouen Baruteau
Journal:  Pediatr Cardiol       Date:  2015-01-06       Impact factor: 1.655

2.  Recombinant Tissue Plasminogen Activator in the Treatment of Neonates with Intracardiac and Great Vessels Thrombosis.

Authors:  Milad El-Segaier; Muhammad A Khan; Zaheer Ullah Khan; Tarek Momenah; Mohammed Omar Galal
Journal:  Pediatr Cardiol       Date:  2015-05-21       Impact factor: 1.655

3.  An institutional approach to interventional strategies for complete vascular occlusions.

Authors:  Philip T Thrush; Chad A Mackman; Paul Lawrence; Aymen Naguib; Andrew R Yates; Stephen D Cassidy; Joanne L Chisolm; Sharon L Hill; John P Cheatham; Ralf J Holzer
Journal:  Pediatr Cardiol       Date:  2011-04-10       Impact factor: 1.655

4.  Transcatheter recanalization of acutely occluded modified systemic to pulmonary artery shunts in infancy.

Authors:  N Sreeram; M Emmel; L Ben-Mime; K Brockmeier; G Bennink
Journal:  Clin Res Cardiol       Date:  2007-11-28       Impact factor: 5.460

5.  Techniques for transcatheter recanalization of completely occluded vessels and pathways in patients with congenital heart disease.

Authors:  Larry A Latson; Athar M Qureshi
Journal:  Ann Pediatr Cardiol       Date:  2010-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.